FibroBiologics, Inc. (NASDAQ:FBLG) Shares Bought by Barclays PLC

Barclays PLC increased its holdings in FibroBiologics, Inc. (NASDAQ:FBLG) by 363.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,958 shares of the company’s stock after purchasing an additional 31,331 shares during the period. Barclays PLC owned 0.12% of FibroBiologics worth $123,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Fund Evaluation Group LLC purchased a new stake in FibroBiologics in the second quarter valued at approximately $5,265,000. Geode Capital Management LLC boosted its position in FibroBiologics by 90.0% during the 3rd quarter. Geode Capital Management LLC now owns 599,760 shares of the company’s stock worth $1,854,000 after purchasing an additional 284,047 shares during the period. Jane Street Group LLC acquired a new stake in FibroBiologics in the 3rd quarter valued at $37,000. State Street Corp raised its position in FibroBiologics by 26.5% in the third quarter. State Street Corp now owns 475,837 shares of the company’s stock valued at $1,470,000 after purchasing an additional 99,789 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of FibroBiologics during the second quarter worth about $342,000.

FibroBiologics Stock Down 5.3 %

FibroBiologics stock opened at $1.60 on Friday. FibroBiologics, Inc. has a 12 month low of $1.08 and a 12 month high of $55.00. The company has a fifty day moving average price of $2.25 and a two-hundred day moving average price of $2.83.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on FBLG. D. Boral Capital reaffirmed a “buy” rating and issued a $16.00 price objective on shares of FibroBiologics in a research report on Friday, December 27th. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of FibroBiologics in a research report on Wednesday, November 13th. Finally, Rodman & Renshaw started coverage on shares of FibroBiologics in a research report on Thursday, December 12th. They set a “buy” rating and a $12.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, FibroBiologics presently has an average rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.